Literature DB >> 4723268

Pharmacokinetics and metabolism of adriamycin in man.

R S Benjamin, C E Riggs, N R Bachur.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4723268     DOI: 10.1002/cpt1973144part1592

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  49 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Cardiotoxic effects of anthracyclines.

Authors:  M R Bristow
Journal:  West J Med       Date:  1983-09

4.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

Authors:  B K Chang; J A Gregory
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  CCNU-adriamycin association induces earlier and more severe nephropathy in rats.

Authors:  G Raguenez-Viotte; M Lahoue; T Ducastelle; J P Morin; J P Fillastre
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

9.  Clinical, toxicological, and pharmacological studies of combination chemotherapy of adenocarcinoma with adriamycin and Baker's antifolate.

Authors:  S W Hall; T F Tenczynski; R S Benjamin; M A Burgess; M Valdivieso; T L Loo; G P Bodey
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 10.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.